1
|
Poidatz D, Dos Santos E, Gronier H, Vialard F, Maury B, De Mazancourt P, Dieudonné MN. Trophoblast syncytialisation necessitates mitochondrial function through estrogen-related receptor-γ activation. Mol Hum Reprod 2014; 21:206-16. [PMID: 25376642 DOI: 10.1093/molehr/gau102] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Human pregnancy needs a correct placentation which depends on adequate cytotrophoblast proliferation, differentiation and invasion. In this study, using specific mitochondrial respiratory chain inhibitors, we observed a decrease of hormone production (hCG and leptin) and cell fusion of human primary villous cytotrophoblasts (CT). These results demonstrated that mitochondria are involved in the control of CT differentiation process. Moreover, we also observed a decrease of mitochondrial mass associated with an increase of mitochondrial DNA during CT differentiation. Furthermore, lactate production increased during CT differentiation suggesting that anaerobic metabolism was enhanced in differentiated CTs, and that the role of mitochondria in CT fusion is not only related to its energetic function. Otherwise, the orphan nuclear receptor, estrogen-related receptor γ (ERRγ) is known to orchestrate transcriptional control of energy metabolism genes. In this study, using RNA knockdown and transcriptional activation with DY131 (an ERRγ agonist), we clearly demonstrated that ERRγ promotes hormone production and cell fusion indicating that ERRγ is a key positive transcriptional factor involved in CT differentiation. Finally, we showed that ERRγ promotes mitochondrial biogenesis and function during CT differentiation, and that the role of ERRγ during trophoblast differentiation is mainly mediated by the control of mitochondrial functions.
Collapse
Affiliation(s)
- Dorothée Poidatz
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France
| | - Esther Dos Santos
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France Service de biologie médicale, CHI de Poissy-st-Germain, 78300 Poissy, France
| | - Héloïse Gronier
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France
| | - François Vialard
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France Département de Biologie de la Reproduction, Cytogénétique, Gynécologie et Obstétrique, CHI de Poissy-st-Germain, 78300 Poissy, France
| | - Benoit Maury
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France
| | - Philippe De Mazancourt
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France Service de biochimie et génétique moléculaire, Hôpital A. Paré, 92100 Boulogne, France
| | - Marie-Noëlle Dieudonné
- UPRES-EA 2493, Université de Versailles-St Quentin, UFR des sciences de la santé, 2 avenue de la source de la Bièvre, 78180 Montigny le Bretonneux, France
| |
Collapse
|
2
|
Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications. Clin Dev Immunol 2013; 2013:159124. [PMID: 23983765 PMCID: PMC3745904 DOI: 10.1155/2013/159124] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 07/08/2013] [Indexed: 11/18/2022]
Abstract
Antiphospholipid syndrome (APS) is an acquired thrombophilia with clinical manifestations associated with the presence of antiphospholipid antibodies (aPL) in patient plasma. Obstetrical APS is a complex entity that may affect both mother and fetus throughout the entire pregnancy with high morbidity. Clinical complications are as various as recurrent fetal losses, stillbirth, intrauterine growth restriction (IUGR), and preeclampsia. Pathogenesis of aPL targets trophoblastic cells directly, mainly via proapoptotic, proinflammatory mechanisms, and uncontrolled immunomodulatory responses. Actual first-line treatment is limited to low-dose aspirin (LDA) and low-molecular weight heparin (LMWH) and still failed in 30% of the cases. APS pregnancies should be a major field in obstetrical research, and new therapeutics are still in progress.
Collapse
|